Changing Prognosis Of Metastatic Colorectal Adenocarcinoma (Mcrc) 1988-2008 Within The General Population: Has Everyone Benefitted?

e14143 Background: Between 1991 and 2008 the FDA approved 7 new drugs for the treatment of mCRC. The results of randomized phase III trials, performed on selected (e.g. younger) patient populations, may not reflect net benefit seen within the general population. We therefore performed a population-based survival analysis of patients who initially presented with mCRC. Methods: Survival statistics were extracted from the Survival, Epidemiology and End Results (SEER) Database for patients diagnosed with mCRC between 1988-2008. Survival was analyzed using the Kaplan-Meier method and proportional hazard models as appropriate. Exclusion criteria included diagnosis at autopsy, non-adenocarcinoma and unknown histology. Results: The study population consisted of 42,347 patients diagnosed with mCRC from 1988-2008, 52% female. Mean age 67 years; 46% were aged 70 or over. Prognostic variables included race, gender, age, marital status, disease site, surgical resection and year of diagnosis (for all pu003c0.001). For the ...